Akèy › Timè Wilms
Etid klinik pou Timè Wilms ap rekrite nan Etazini
17 etid pou Timè Wilms ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Washington, DC7 etid
- Memphis, TN6 etid
- Atlanta, GA5 etid
- Boston, MA4 etid
- Los Angeles, CA4 etid
- Chicago, IL4 etid
- St. Louis, MO4 etid
- Minneapolis, MN4 etid
- Greenburgh, NY4 etid
- Mountain View, CA4 etid
- Houston, TX4 etid
- New York City, NY4 etid
- Cincinnati, OH4 etid
- Philadelphia, PA4 etid
- Aurora, CO4 etid
- Ann Arbor, MI3 etid
- Birmingham, AL3 etid
Pa eta
- Alabama3 etid
- Colorado4 etid
- Distrik Columbia7 etid
- Florid3 etid
- Georgia5 etid
- Illinois4 etid
- Kalifòni5 etid
- Massachusetts4 etid
- Michigan3 etid
- Minnesota5 etid
- Missouri4 etid
- New York6 etid
- Ohio5 etid
- Pennsylvania4 etid
- Tennessee6 etid
- Texas6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 29, 2026 · NCT04616560Biomarkers of Resiliency In Childhood Cancer Surgery
Ap rekriteEtid obsèvasyon
Laj 3 a 25 · Tout sèks · Mizajou Sep 14, 2026 · NCT06674811A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Ap rekriteFaz 2
Jiska laj 30 · Tout sèks · Mizajou Aug 25, 2026 · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Ap rekriteFaz 1
Laj 1 a 23 · Tout sèks · Mizajou Aug 13, 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Jun 30, 2026 · NCT06625190B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou May 19, 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Ap rekriteFaz 2
12 Months · Tout sèks · Mizajou May 6, 2026 · NCT05985161Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Apr 23, 2026 · NCT04968990Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Apr 15, 2026 · NCT04308330Pencil Beam Scanning in Patients With Renal Tumors
Ap rekriteFaz 1 bonè
Laj 0 a 30 · Tout sèks · Mizajou Apr 15, 2026 · NCT03810651Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Ap rekriteFaz 2
18 Months – 40 Years · Tout sèks · Mizajou Aug 12, 2025 · NCT05135975International PPB/DICER1 Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
0 Minutes – 100 Years · Tout sèks · Mizajou Jan 30, 2025 · NCT03382158Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.